Inhibitors of MIF are provided which have utility in the treatment of a
variety of disorders, including the treatment of pathological conditions
associated with MIF activity. The inhibitors of MIF have the following
structures: including stereoisomers, prodrugs and pharmaceutically
acceptable salts thereof, wherein n, R.sub.1, R.sub.2, R.sub.3, R.sub.4,
X, Y and Z are as defined herein. Compositions containing an inhibitor of
MIF in combination with a pharmaceutically acceptable carrier are also
provided, as well as methods for use of the same.